Previous 10 | Next 10 |
RAMSEY, N.J. and BOCA RATON, Fla., Nov. 10, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived bi...
Pfizer and BioNTech's announcement that their COVID-19 vaccine candidate showed 90% efficacy based on a preliminary analysis of results from a pivotal study has stoked selling in therapy developers. If the higher-than-expected efficacy holds, herd immunity in the general population could pote...
Image source: The Motley Fool. ADMA Biologics Inc (NASDAQ: ADMA) Q3 2020 Earnings Call Nov 6, 2020 , 8:00 p.m. ET Operator Continue reading For further details see: ADMA Biologics Inc (ADMA) Q3 2020 Earnings Call Transcript
Assembly Biosciences (ASMB) -55% on Q3 earnings release.Global Blood Therapeutics (GBT) -32% on Q3 earnings release.Epizyme (EPZM) -23% on Q3 earnings release.Marin Software (MRIN) -14% on Q3 earnings release.Hall of Fame Resort & Entertainment (HOF...
ADMA Biologics, Inc. (ADMA) Q3 2020 Earnings Conference Call November 5, 2020 4:30 PM ET Company Participants Skyler Bloom – Director-Investor Relations and Corporate Strategy Adam Grossman – President and Chief Executive Officer Brian Lenz – Executive Vice President and ...
ADMA Biologics (ADMA): Q3 GAAP EPS of -$0.19 beats by $0.01.Revenue of $10.28M (+42.4% Y/Y) beats by $0.46M.Shares +1.9%.Press Release For further details see: ADMA Biologics EPS beats by $0.01, beats on revenue
Generated Total Revenues of $ 28. 3 Million for the First Nine Months of 2020 , Reflecting a 63 % Increase Over the Same Prior Year Period Successfully Opened Newest ADMA BioCenters Plasma Collection Facility; On Tr...
RAMSEY, N.J. and BOCA RATON, Fla., Oct. 29, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced the Co...
RAMSEY, N.J. and BOCA RATON, Fla., Oct. 21, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived bi...
A recent 10-Q for IBIO mentions the word "plasma" just once. IBIO isn't a plasma company like ADMA and isn't developing a plasma-derived product for COVID-19 like KMDA. IBIO can make proteins in plants, such as plasma proteins, so can other. IBIO is late to the game with a recent ...
News, Short Squeeze, Breakout and More Instantly...
2024-05-10 11:30:04 ET Raymond James analyst issues STRONG BUY recommendation for ADMA on May 10, 2024 09:52AM ET. The previous analyst recommendation was Strong Buy. ADMA was trading at $8.705 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...